ANTI-BETA-AMYLOID (13-28) ANTIBODY

Description_x000D_ General description_x000D_ Amyloids are insoluble protein aggregates consisting of misfolded proteins and peptides. Amyloid deposition are associated with multiple neurodegenerative disorders._x000D_ The β-amyloid precursor protein (APP) is cleaved sequentially by the proteolytic enzymes β-secretase (BACE1) and γ-secretase to produce β-amyloid (Aβ) peptides with the Aβ1-42 and the Aβ1-40 forms being the most prevalent. Secreted Aβ peptides are degraded either via a re-uptake mechanism followed by endosomal degradation, or by an extracellular insulin degrading enzyme. Extracellular accumulation of Aβ leads to the formation of aggregates, fibrils and eventually amyloid deposits called neuritic plaques, which is the hallmark of Alzheimer′s disease (AD)._x000D_ Monoclonal Anti β-Amyloid [13-28] recognizes the β-Amyloid peptide. The antibody epitope resides within amino acids 20-23._x000D_ Application_x000D_ Applications in which this antibody has been used successfully, and the associated peer-reviewed papers, are given below._x000D_ Immunohistochemistry (1 paper)_x000D_ Mouse Monoclonal Anti-β-Amyloid (13-28) antibody can be used for immunoblotting assays at 1:5,000. The antibody can also be used for IHC, immunoprecipitation,fluorescence infrared spectroscopy and enzyme immunoassays (02-0.4μg/ml)._x000D_ Physical form_x000D_ Filtered solution in 0.01 M phosphate buffered saline, pH 7.4._x000D_ Disclaimer_x000D_ Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.